Insoles, removable shoe inserts cushioning or supporting the foot, are a targeted tool for specific foot, knee and diabetic problems, not a general longevity measure. Strongest evidence: protecting numb diabetic feet from new wounds, when worn. Heel, kneecap and Achilles pain relief is modest and mostly short-lived; inner-knee arthritis and back pain show no reliable benefit over flat insoles. Downsides: blisters, discomfort and poorer standing balance with very soft cushioning. (Full Review)

Protocol

Prefabricated-first approach

Contoured insoles first

Custom devices reserved for deformity or failure

Diabetic high-risk feet

All steps, including indoors

Custom pressure-optimized insoles in extra-depth footwear

Patellofemoral pain regimen

About 6 weeks

Prefabricated orthoses fitted for comfort, with exercise therapy as the core

Time to effect

Pressure redistribution

Immediate

Diabetic ulcer protection depends on consistent daily wear

Heel pain

7–12 weeks

Benefit over placebo-like devices only in this window

Kneecap pain

Within about 6 weeks

No benefit shown beyond three months

Benefits

High: Prevention of recurrent diabetic foot ulcers; relief of foot pain

Medium: Short-term relief of kneecap pain; better balance and fewer falls in older adults; Achilles tendon pain relief with heel lifts

Low: Fewer overuse injuries and stress fractures; inner-knee arthritis pain; chronic low back pain

Speculative: Sustaining walking and activity volume

Contraindications

Active ulcer on the sole of the foot

Active Charcot foot (skin temperature more than 2 °C above the other foot)

Critical limb ischemia (ankle-brachial index below 0.5 or rest pain)

Lateral wedges: outer-knee osteoarthritis or valgus (knock-knee) alignment

Soft, thick cushioned insoles: older adults at high fall risk (Timed Up and Go of 13.5 seconds or more) without a balance assessment

Key Interactions

Neuropathy-causing prescription drugs (paclitaxel, oxaliplatin, vincristine)

Anticoagulants and corticosteroids (warfarin, apixaban; long-term oral prednisone)

Over-the-counter medications (regular analgesics: ibuprofen, naproxen, acetaminophen)

Physiotherapy and exercise

Footwear (shallow or narrow shoes)

Risk & Side Effects

High: Skin irritation, blisters and device discomfort; higher energy cost of running

Medium: Impaired standing balance with soft insoles

Low: Weakening of the small muscles inside the foot; load transfer to the ankle and hip with lateral wedges

Monitoring

Marker	Target	Why
Walking pain (0–10 numeric rating scale)	No established target; aim for 0–2, or a drop of at least 2 points from baseline	Tracks the main benefit
Timed Up and Go	Under 10 seconds	Balance and mobility
10 g monofilament sensation	All tested sole sites felt	Detects loss of protective sensation
In-shoe peak plantar pressure	Below 200 kPa at high-risk sites	Verifies offloading
HbA1c	4.8–5.4%	Glycemic control drives neuropathy and ulcer risk
Ankle-brachial index	1.0–1.3	Confirms circulation adequate for rigid devices

Cadence: Skin checks daily for the first 2 weeks (indefinitely for numb feet); symptom and fit review at 2 weeks; pain or balance reassessment at 6–12 weeks, then every 6–12 months; diabetes with loss of sensation every 1–3 months

Qualitative Assessment

Walking distance or daily steps without foot, knee or heel pain
Morning first-step heel pain
Comfort and willingness to wear the insoles all day
Confidence and steadiness on stairs and uneven ground
Absence of blisters, persistent redness or new calluses
Ability to complete training sessions without symptom flares

Insoles for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment